文献速递骨软组织肉瘤与黑色素瘤

Vibostolimab联合帕博利珠单抗对比帕博利珠单抗单药辅助治疗高危IIB-IV期黑色素瘤的III期研究

Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study.
PubMed 文献 · Lancet Oncol · 2026-02-13

KEYVIBE-010是一项随机双盲III期研究,纳入1402例已切除的高危IIB-IV期皮肤黑色素瘤患者,比较Vibostolimab联合帕博利珠单抗与帕博利珠单抗单药的辅助治疗。研究因预设无效性标准提前终止,帕博利珠单抗单药仍是标准治疗。

要点

  • 联合组治疗相关严重不良事件发生率为11%,高于单药组的4%。
  • 因预设无效性标准,研究提前终止,帕博利珠单抗单药仍为标准。

核心结论

  • Vibostolimab联合帕博利珠单抗对比帕博利珠单抗单药辅助治疗已切除高危IIB-IV期黑色素瘤,未提供额外临床获益。
  • 帕博利珠单抗单药仍是已切除高危黑色素瘤的标准治疗。

研究设计与样本

  • 随机、双盲、III期研究,在205个全球站点(医院和癌症中心)开展。
  • 纳入年龄≥12岁、经手术切除的IIB-IV期皮肤黑色素瘤(AJCC第8版2017),切除后无转移证据。
  • 按1:1随机分配至Vibostolimab 200 mg联合帕博利珠单抗200 mg或帕博利珠单抗200 mg单药,每3周静脉给药。
  • 随机化按风险分期和地理区域分层,主要终点为意向治疗人群的无复发生存。
  • 共1402例参与者随机分配(联合组n=701,单药组n=701)。

主要发现

  • 联合组最常见的≥3级治疗相关不良事件包括肾上腺功能不全13例(2%)、肝炎11例(2%)、皮疹9例(1%)、斑丘疹7例(1%)、瘙痒6例(1%);单药组为丙氨酸氨基转移酶升高7例(1%)。
  • 治疗相关严重不良事件在联合组74例(11%)、单药组30例(4%)中发生。
  • 治疗相关不良事件导致死亡:联合组2例(<1%,重症肌无力和心肌炎),单药组1例(<1%,肌炎)。

关键数值与推荐

  • 外部数据监测委员会根据预设无效性标准决定终止研究。

临床怎么用

  • 对于已切除的高危IIB-IV期黑色素瘤,不推荐在帕博利珠单抗基础上联合Vibostolimab作为辅助治疗。
  • 帕博利珠单抗单药应继续作为该人群的标准辅助治疗选择。

局限性

  • 研究因无效性提前终止,未提供长期生存或最终分析数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Combination therapy with vibostolimab plus pembrolizumab has previously shown promising antitumor activity in melanoma. We aimed to evaluate the efficacy and safety of vibostolimab coformulated with pembrolizumab as adjuvant therapy for high-risk resected melanoma. METHODS: This randomised, double-blind, phase 3 study was done at 205 global sites (hospitals and cancer centres). Participants aged 12 years or older with surgically resected, stage IIB-IV cutaneous melanoma per the American Joint Committee on Cancer Cancer Staging Manual 2017 (8th edition), with no evidence of metastatic disease after resection, were randomly assigned (1:1) to receive vibostolimab 200 mg coformulated with pembrolizumab 200 mg or pembrolizumab 200 mg alone intravenously every 3 weeks. Randomisation was done using an interactive response technology system and was stratified by risk-based staging and geographical region. Participants, investigators, and site staff were masked to group assignment. The primary endpoint was recurrence-free survival assessed in the intention-to-treat population. Safety was assessed in all participants who received at least one dose of the study treatment. The protocol-prespecified first interim analysis was an event-driven nonbinding futility analysis of recurrence-free survival that was planned for when 111 events had occurred (futility bar of observed HR 0·95). This study is registered with ClinicalTrials.gov (NCT05665595), and is closed to recruitment. FINDINGS: Between Jan 19, 2023, and March 6, 2024, 1402 participants were randomly assigned to receive coformulated vibostolimab-pembrolizumab (n=701) or pembrolizumab (n=701). At the first interim analysis, median study follow-up, defined as time from randomisation to data cutoff, was 4·2 months (IQR 1·9-6·7). The median age was 61·0 years (IQR 51·0-70·0), 829 (59%) of 1402 participants were male and 573 (41%) were female. 1107 (79%) of participants were White, 273 (19%) were Asian, and 22 (2%) were of other race or race was missing. At the time of the first interim analysis, a total of 119 (8%) of 1402 participants had had a recurrence-free survival event, including 67 (10%) of 701 in the vibostolimab-pembrolizumab group and 52 (7%) of 701 in the pembrolizumab alone group. The median recurrence-free survival was not reached in either group; the hazard ratio for recurrence-free survival in the vibostolimab-pembrolizumab group versus pembrolizumab alone group was 1·25 (95% CI 0·9-1·8). The most common (occurred in more than five participants) grade 3 or higher treatment-related adverse events were adrenal insufficiency in 13 (2%) participants, hepatitis in 11 (2%) participants, rash in 9 (1%) participants, maculopapular rash in 7 (1%) participants, and pruritus in 6 (1%) participants in the vibostolimab-pembrolizumab group and increased alanine aminotransferase in 7 (1%) participants in the pembrolizumab alone group. Treatment-related serious adverse events occurred in 74 (11%) participants and 30 (4%) participants, respectively. Treatment-related adverse events led to death in two (<1%) participants in the vibostolimab-pembrolizumab group (myasthenia gravis and myocarditis) and one participant (<1%) in the pembrolizumab group (myositis). The external data monitoring committee decided to discontinue the study according to prespecified futility criteria. INTERPRETATION: Vibostolimab coformulated with pembrolizumab did not provide additional clinical benefit versus pembrolizumab as adjuvant therapy in participants with resected stage IIB-IV melanoma. Pembrolizumab monotherapy remains a standard of care for resected high-risk melanoma. FUNDING: Merck Sharp & Dohme, a subsidiary of Merck & Co.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Dummer R, Guo J, Luke JJ, et al. Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study. Lancet Oncol. 2026. PMID: 41698381. doi:10.1016/S1470-2045(25)00709-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。